Unusual Increased Blood Pool Activity on 68Ga-DOTATATE PET/CT in a Patient With Metastatic Neuroendocrine Disease. (February 2022)

• Record Type: Journal Article
• Authors: Sharma, Akash; Navaz, Anem J.; Pandey, Mukesh K.; Parent, Ephraim E.
• Is Part Of: Clinical nuclear medicine. Volume 47:Number 2(2022)
• Publication Date: 2022-02
• Subjects: 68Ga-DOTATATE PET/CT -- somatostatin receptor -- neuroendocrine tumor -- blood pool; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000003940
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: 68 Ga-DOTATATE is a well-established, positron-emitting, somatostatin receptor–binding radiopharmaceutical. We present an unusual case of transiently increased blood pool uptake of 68 Ga-DOTATATE in a patient with well-differentiated stage IV neuroendocrine tumor, with Ki-67 <2% (WHO grade 1) maintained on lanreotide. During serial 68 Ga-DOTATATE PET/CT examinations, increased blood pool accumulation of presumably unbound 68 Ga was demonstrated, which could impact the Kenning score and lead to a false treatment response assessment.